Desidustat VS Darbepoetin in anemia of chronic kidney disease patients undergoing maintenance haemodialysis
Not Applicable
- Conditions
- Health Condition 1: N185- Chronic kidney disease, stage 5
- Registration Number
- CTRI/2023/07/054621
- Lead Sponsor
- Kalinga institute of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Maintenance Haemodialysis Patients with Hb8-11 g/dl in chronic kidney disease.
Exclusion Criteria
Patient with iron deficiency anemia .
History of Bleeding disorders.
Red blood cell transfusion within 8 weeks prior to enrollment.
History of previous or concurrent cancer.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients reaching target haemoglobin(Hb g/dl) who are receiving desidustat.Timepoint: follow up at 4weeks 8weeks <br/ ><br> & 12weeks
- Secondary Outcome Measures
Name Time Method Saftey of desidustat. <br/ ><br> <br/ ><br>Timepoint: follow up at 4weeks 8weeks 12 weeks <br/ ><br> <br/ ><br>